4-苄氧基-3-溴苯胺 | 320337-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-苄氧基-3-溴苯胺
• 英文名称: 4-benzyloxy-3-bromoaniline
• 英文别名: 3-bromo-4-(benzyloxy)-aniline；4-amino-1-benzyloxy-2-bromobenzene；4-Benzyloxy-3-bromophenylamine；3-bromo-4-phenylmethoxyaniline
• CAS: 320337-15-3
• 化学式: C₁₃H₁₂BrNO
• mdl: MFCD16085548
• 分子量: 278.148
• InChiKey: CWOYDLZVKUVCEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苄氧基-3-溴苯胺 在 palladium diacetate 、 三乙胺 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 生成 5-(4-(3-Bromo-4-(benzyloxy)-anilino)-quinazolin-6-yl)-furan-2-carbaldehyde
  参考文献：
  名称：

  Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

  摘要：

  Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.090
• 作为产物：
  描述：

  2-溴-4-硝基苯酚 在 tin(II) chloride dihdyrate 、 potassium carbonate 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 反应 5.0h， 生成 4-苄氧基-3-溴苯胺
  参考文献：
  名称：

  A practical nickel-catalyzed reductive alkylation of amidophenyl bromides

  摘要：

  A modified Weix's reductive coupling for alkylation of amidoaryl bromides based on Ni(COD)(2) precatalyst and 2,2'-dipyridyl ligand was developed. This reaction is reliable for amidophenyl bromides and gives yields up to 87%, and is potentially useful in the synthesis of amidophenyl-containing molecules. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.10.061

文献信息

• [EN] IMIDAZOLIDINEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINEDIONE
  申请人：GLAXO GROUP LTD

  公开号：WO2011069951A1

  公开（公告）日：2011-06-16

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

  这项发明提供了化合物(Ia)及其药学上可接受的盐。该发明还提供了将这些化合物或盐用作Kv3.1和/或Kv3.2的调节剂，以及在需要Kv3.1和/或Kv3.2调节剂的疾病或紊乱的治疗中的用途，如抑郁症和情绪障碍、听觉障碍、精神分裂症、物质滥用障碍、睡眠障碍或癫痫病。
• Anilinoquinazaolines as protein tyrosine kianse inhibitors
  申请人：Cockerill Stuart George

  公开号：US20050143401A1

  公开（公告）日：2005-06-30

  Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

  本发明描述了杂环芳香化合物，它们的制备方法，含有它们的药物组合物，使用方法以及它们在药物中的应用。特别是，本发明涉及表现出蛋白酪氨酸激酶抑制活性的喹唑啉和吡啶嘧啶衍生物。
• Functionalized alkoxy arene diazonium salts from paracetamol
  作者：Bernd Schmidt、René Berger、Frank Hölter

  DOI：10.1039/b924619c

  日期：——

  as a convenient one-flask transformation with consecutive addition of the appropriate reagents. Exchange of solvents or removal of byproducts prior to isolation of the product is not required. The arene diazonium salts are isolated from the reaction mixture by simple filtration. Two complementary protocols are presented, and the utility of the reaction is exemplified for a synthesis of the diarylheptanoid

  芳族乙酰胺四氟硼酸酯可以由芳族乙酰胺经一系列的脱乙酰基，重氮化和沉淀（由阴离子交换诱导）合成。该反应以方便的一瓶转化进行，并连续添加适当的试剂。不需要在分离产物之前交换溶剂或除去副产物。通过简单的过滤从反应混合物中分离出芳烃重氮盐。提出了两种互补的方案，并举例说明了该反应用于合成二芳基庚烷天然产物去-O-甲基中心洛宾的方法。
• Novel compounds that are ERK inhibitors
  申请人：Deng Yongqi

  公开号：US20070232610A1

  公开（公告）日：2007-10-04

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及一种化学式1.0的ERK抑制剂，以及其药学上可接受的盐和溶剂。其中，Q为一个哌啶或哌嗪环，可以有一个桥或一个融合环。哌啶环中可以在环中有一个双键。所有其他取代基如定义所述。本发明还涉及使用化合物1.0治疗癌症的方法。
• HETEROCYCLIC COMPOUNDS
  申请人：Cockerill Stuart George

  公开号：US20080004294A1

  公开（公告）日：2008-01-03

  Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

  本发明涉及杂环芳香化合物、其制备方法、含有它们的药物组合物、使用方法以及它们在药物中的应用。特别地，本发明涉及能够抑制蛋白酪氨酸激酶的喹嗪啉和吡啶并嘧啶衍生物。